Related Experiment Video
Updated: Jun 22, 2026
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Beryllium hypersensitivity and chronic beryllium lung disease
1Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USA. lsantot@mcw.edu
Current Opinion in Pulmonary Medicine
|June 18, 2009
Summary
Reducing beryllium exposure and implementing preventive measures can decrease the risk of beryllium hypersensitivity (BeH) and chronic beryllium disease (CBD). Early detection via BeLPT aids diagnosis, but treatment strategies require further research.
Area of Science:
- Pulmonary Medicine
- Occupational Health
- Immunology
Background:
- Beryllium exposure can lead to beryllium hypersensitivity (BeH) and chronic beryllium disease (CBD).
- Understanding the epidemiology and pathogenesis of BeH and CBD is crucial for clinical management.
- Recent advancements have shed light on the mechanisms underlying beryllium-related lung diseases.
Purpose of the Study:
- To synthesize recent research on the epidemiology and pathogenesis of BeH and CBD.
- To provide clinicians with an updated understanding of beryllium-associated lung diseases.
- To highlight areas for future research in prevention and treatment.
Main Methods:
- Literature review of recent studies on beryllium hypersensitivity and chronic beryllium disease.
- Analysis of epidemiological data and pathogenetic mechanisms.
- Synthesis of findings related to diagnosis, risk factors, and genetic associations.
Main Results:
- Lower occupational exposure limits and stringent preventive measures reduce the risk of BeH and CBD.
- Beryllium sensitization is identified by a positive beryllium lymphocyte proliferation test (BeLPT).
- Longitudinal data indicate BeH can progress to CBD; BeLPT aids in differentiating from sarcoidosis.
- HLA-DPB1-Glu69 is associated with susceptibility, but its predictive value is limited; other genetic markers are under investigation.
- T-lymphocytes and chemokines play a role in beryllium-associated disease pathogenesis.
Conclusions:
- Enhanced understanding of beryllium-associated lung disease may offer insights into other granulomatous diseases.
- Further research is needed to translate current knowledge into improved prevention and treatment strategies.
- Elucidation of remaining questions in beryllium disease pathogenesis and management is essential.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: